| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1394e66eb648f9bf0a1f5507fe25b67b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81a2621945dd5995f57f121230077dd5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate |
2020-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6867ab32039a5874a21b06bc500a7607
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_068d866a47b37d6e464a76682509db64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9475617d1aef5a00ed5ca9df3c7ad7f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9bd7039db68497fb02086cb7b201e4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2626b1dee5e4ec285503b133d76da441 |
| publicationDate |
2021-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202106300-A |
| titleOfInvention |
Combination therapy with immune checkpoint inhibitors using quinoline carboxamide derivatives |
| abstract |
The present invention provides a method for using a STAT3 inhibitor that exerts an excellent anti-tumor effect.nThe antitumor agent of the present invention uses the quinoline carboxamide derivative represented by the following formula (I) or its salt as an active ingredient, and is administered in combination with an immune checkpoint inhibitor, and is administered to the immune checkpoint inhibitor Vote before. |
| priorityDate |
2019-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |